<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499147</url>
  </required_header>
  <id_info>
    <org_study_id>2000-0117</org_study_id>
    <nct_id>NCT01499147</nct_id>
  </id_info>
  <brief_title>Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies</brief_title>
  <official_title>Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      New conditioning regimens are still needed to maximize efficacy and limit treatment-related
      deaths of allogeneic transplantation for advanced hematologic malignancies. Over the past
      several years, the investigators have evaluated several new conditioning regimens that
      incorporate fludarabine, a novel immunosuppressant that has limited toxicity and that has
      synergistic activity with alkylating agents. Recent data have suggested that fludarabine may
      be used in combination with standard doses of oral or IV busulfan, thus reducing the toxicity
      previously observed with cyclophosphamide/ busulfan regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment-related mortality and recurrence of disease account for the majority of treatment
      failures in allogeneic transplantation for advanced hematologic malignancies. The most
      commonly utilized conditioning regimens consist of cyclophosphamide and total-body
      irradiation or busulfan and cyclophosphamide. Other agents such as etoposide or thiotepa are
      sometimes added to maximize the antileukemic effect. New conditioning regimens are however
      still needed to maximize efficacy and limit treatment-related deaths. Over the past several
      years, the investigators have evaluated several new conditioning regimens that incorporate
      fludarabine, a novel immunosuppressant that has limited toxicity and that has synergistic
      activity with alkylating agents. Recent data have suggested that fludarabine may be used in
      combination with standard doses of oral or IV busulfan, thus reducing the toxicity previously
      observed with cyclophosphamide/ busulfan regimens.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Engraftment.</measure>
    <time_frame>Up to 30 days post-transplant</time_frame>
    <description>Median time to ANC engraftment and platelet engraftment in both groups as well as the transfusion requirements measured within 30 days after transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With 100 Day Transplant-related Mortality.</measure>
    <time_frame>Up to 100 days post-transplant.</time_frame>
    <description>Day 100 transplant-related mortality was measured in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ANC and Platelet Engraftment</measure>
    <time_frame>Up to 30 days post-transplant</time_frame>
    <description>Days to engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Moderate to Severe (Grade 2-4) Acute Graft Versus Host Disease (GVHD).</measure>
    <time_frame>Up to 100 days post-transplant (acute GVHD).</time_frame>
    <description>Acute GVHD grade 2-4 was assessed in patients in the FluBU and FluMel groups up to 100 days after transplant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Malignant Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphocytic Leukemia</condition>
  <condition>Myeloproliferative Disorder</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Myelofibrosis</condition>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine/busulfan</intervention_name>
    <description>All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Fludarabine:</other_name>
    <other_name>Fludarabine Phosphate</other_name>
    <other_name>Fludara</other_name>
    <other_name>Busulfan:</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine/ melphalan</intervention_name>
    <description>All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl).</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Fludarabine:</other_name>
    <other_name>Fludarabine phosphate</other_name>
    <other_name>Fludara</other_name>
    <other_name>Melphalan:</other_name>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG</intervention_name>
    <description>Patients receiving a transplant from a matched unrelated or mismatched related/unrelated donor would receive ATG in the conditioning regimen.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the following diseases:

               -  Acute myeloid or lymphocytic leukemia in first remission at standard or high-risk
                  for recurrence.

               -  Acute leukemia in greater than or equal to second remission, or with early
                  relapse, or partial remission.

               -  Chronic myelogenous leukemia in accelerated phase or blast-crisis.

               -  Chronic myelogenous leukemia in chronic phase

               -  Recurrent or refractory malignant lymphoma or Hodgkin's disease

               -  Multiple myeloma.

               -  Chronic lymphocytic leukemia, relapsed or with poor prognostic features.

               -  Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor
                  prognostic features.

               -  Severe aplastic anemia after failure of immunosuppressive therapy.

          -  Age 10-65 years.

          -  Zubrod performance status less than or equal to 2.

          -  Adequate cardiac and pulmonary function. Patients with decreased LVEF &lt; 40% or DLCO &lt;
             50% of predicted will be evaluated by cardiology or pulmonary prior to enrollment on
             this protocol.

          -  Patient or guardian able to sign informed consent.

        Exclusion Criteria:

          -  Life expectancy is severely limited by concomitant illness.

          -  Serum creatinine greater than 1.5 mg/dL or Creatinine Clearance less than 50 ml/min .

          -  Serum bilirubin greater than or equal to 2.0 mg/dl, SGPT greater than 3 x upper limit
             of normal

          -  Evidence of chronic active hepatitis or cirrhosis

          -  HIV-positive

          -  Patient is pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damiano Rondelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>December 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <results_first_submitted>June 19, 2015</results_first_submitted>
  <results_first_submitted_qc>May 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Damiano Rondelli, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>First remission</keyword>
  <keyword>Acute lymphocytic leukemia</keyword>
  <keyword>Acute leukemia</keyword>
  <keyword>Second remission</keyword>
  <keyword>Early relapse</keyword>
  <keyword>Partial remission</keyword>
  <keyword>Accelerated phase</keyword>
  <keyword>Blast-crisis</keyword>
  <keyword>Chronic myelogenous leukemia</keyword>
  <keyword>Chronic phase</keyword>
  <keyword>Recurrent malignant lymphoma</keyword>
  <keyword>Refractory malignant lymphoma</keyword>
  <keyword>Hodgkin's disease</keyword>
  <keyword>Multiple myeloma.</keyword>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>Myeloproliferative disorder</keyword>
  <keyword>Polycythemia vera</keyword>
  <keyword>Myelofibrosis</keyword>
  <keyword>Severe aplastic anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Vidarabine Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We analyzed the clinical outcome of patients with hematological malignancies at standard or high-risk, who were transplanted (allogeneic peripheral blood or BMT HSCT) after receiving FluBU as a conditioning regimen. A total of 30 patients were recruited for this study which was conducted at the UIC Medical Center Inpatient BMT unit.</recruitment_details>
      <pre_assignment_details>Criteria for FluBu conditioning: &lt;60 years old; no diagnosis of myeloma or myelofibrosis (MF) in chronic phase; and not having received an autologous stem cell transplant with the last 2 years. Patients not fulfilling these criteria but still eligible for allogeneic transplantation were prepared with FluMel.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fludarabine/Busulfan + ATG</title>
          <description>All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.
fludarabine/busulfan: All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.</description>
        </group>
        <group group_id="P2">
          <title>Fludarabine/Melphalan + ATG</title>
          <description>All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.
fludarabine/ melphalan: All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.
fludarabine/busulfan: All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.
fludarabine/ melphalan: All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" lower_limit="19" upper_limit="61"/>
                    <measurement group_id="B2" value="49" lower_limit="22" upper_limit="61"/>
                    <measurement group_id="B3" value="42.5" lower_limit="19" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Engraftment.</title>
        <description>Median time to ANC engraftment and platelet engraftment in both groups as well as the transfusion requirements measured within 30 days after transplant.</description>
        <time_frame>Up to 30 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Busulfan + ATG</title>
            <description>All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.
fludarabine/busulfan: All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine/Melphalan + ATG</title>
            <description>All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.
fludarabine/ melphalan: All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Engraftment.</title>
          <description>Median time to ANC engraftment and platelet engraftment in both groups as well as the transfusion requirements measured within 30 days after transplant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With 100 Day Transplant-related Mortality.</title>
        <description>Day 100 transplant-related mortality was measured in both groups.</description>
        <time_frame>Up to 100 days post-transplant.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Busulfan + ATG</title>
            <description>All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.
fludarabine/busulfan: All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine/Melphalan + ATG</title>
            <description>All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.
fludarabine/ melphalan: All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl).</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With 100 Day Transplant-related Mortality.</title>
          <description>Day 100 transplant-related mortality was measured in both groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to ANC and Platelet Engraftment</title>
        <description>Days to engraftment</description>
        <time_frame>Up to 30 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Busulfan + ATG</title>
            <description>All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.
fludarabine/busulfan: All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.
ATG: Patients receiving a transplant from a matched unrelated or mismatched related/unrelated donor would receive ATG in the conditioning regimen.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine/Melphalan + ATG</title>
            <description>All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.
fludarabine/ melphalan: All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl).
ATG: Patients receiving a transplant from a matched unrelated or mismatched related/unrelated donor would receive ATG in the conditioning regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to ANC and Platelet Engraftment</title>
          <description>Days to engraftment</description>
          <units>days to ANC and platelet engraftment</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="0" upper_limit="24"/>
                    <measurement group_id="O2" value="12" lower_limit="10" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Moderate to Severe (Grade 2-4) Acute Graft Versus Host Disease (GVHD).</title>
        <description>Acute GVHD grade 2-4 was assessed in patients in the FluBU and FluMel groups up to 100 days after transplant.</description>
        <time_frame>Up to 100 days post-transplant (acute GVHD).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Busulfan + ATG</title>
            <description>All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.
fludarabine/busulfan: All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine/Melphalan +ATG</title>
            <description>All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.
fludarabine/ melphalan: All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 &lt;40%, DLCO&lt;50%, LVEF&lt;40, Serum bilirubin &gt;1.5 mg% or serum transaminases &gt; 2x nl).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Moderate to Severe (Grade 2-4) Acute Graft Versus Host Disease (GVHD).</title>
          <description>Acute GVHD grade 2-4 was assessed in patients in the FluBU and FluMel groups up to 100 days after transplant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>365 days post-transplant</time_frame>
      <desc>REGIMEN-RELATED TOXICITY ACCORDING TO ORGAN SYSTEM (ref: Bearman et al: J Clin Oncol vol 6, 1988, 1562-1568)</desc>
      <group_list>
        <group group_id="E1">
          <title>Participants With Extra-hematological Toxicities</title>
          <description>We analyzed if different rates of severe extra-hematological toxicities could be detected in patients conditioned with FluBu and FluMel and receiving PBSC.</description>
        </group>
        <group group_id="E2">
          <title>FluBu Participants With Extra-hematological Toxicities</title>
          <description>We analyzed if different rates of severe extra-hematological toxicities could be detected in patients conditioned with FluBu and receiving PBSC.</description>
        </group>
        <group group_id="E3">
          <title>FluMel Participants With Extra-hematological Toxicities</title>
          <description>We analyzed if different rates of severe extra-hematological toxicities could be detected in patients conditioned with FluMel and receiving PBSC.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Bearman criteria</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>stomatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>CMV reactivation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Bearman criteria</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Veno-occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Damiano Rondelli, MD</name_or_title>
      <organization>University of Illinois Cancer Center</organization>
      <phone>312-996-6179</phone>
      <email>drond@uic.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

